PFE vs PG: Which Is the Better Buy?
Side-by-side comparison of Pfizer Inc. and The Procter & Gamble Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-18.
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
VS
The Procter & Gamble Company · Consumer Defensive
$147.04
+14.4% upside to fair value
Med Conviction
Grade B+
High Quality
QuantHub Verdict
PG has more upside to fair value
(+14.4%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
PFE |
PG |
| Current Price |
$27.64 |
$147.04 |
| Fair Value Estimate |
$30.94 |
$168.19 |
| Upside to Fair Value |
+12.0%
|
+14.4%
|
| Market Cap |
$157.5B |
$349.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
17.4x
|
17.6x
|
| Price / Sales |
2.5x
|
4.0x
|
| Price / FCF |
14.3x
|
22.4x
|
| Revenue Growth YoY |
+2.6%
|
+1.5%
|
| Gross Margin |
71.3%
|
50.2%
|
| Operating Margin |
25.1%
|
22.7%
|
| Return on Equity |
4.9%
|
29.8%
|
| Dividend Yield |
6.22% |
2.92% |
| FCF Yield |
6.97%
|
4.47%
|
| Analyst Consensus |
Hold
|
Buy
|
Investment Thesis
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Procter & Gamble is a global consumer-staples leader selling daily-use products across beauty, grooming, health care, fabric and home care, and baby, feminine and family care in about 180 countries. Business quality is high because its brands, consumer insight, R&D, marketing scale and global distribution underpin leading category positions, including over 60% in blades and razors and over 35% in…
Accumulation Zones
| Metric |
PFE |
PG |
| Zone Low |
$23.21 |
$126.14 |
| Zone High |
$26.30 |
$142.96 |
| In Buy Zone? |
No
|
No
|